Cell proliferation measured by MIB1 and timing of surgery for breast cancer.

We have investigated the use of the antibody MIB1 as a proliferative and prognostic marker in breast cancer and whether changes in proliferative activity could account for differences in prognosis of premenopausal women operated on during different phases of the menstrual cycle. MIB1 expression was...

Descripción completa

Detalles Bibliográficos
Autores principales: Cooper, L. S., Gillett, C. E., Smith, P., Fentiman, I. S., Barnes, D. M.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1998
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2150202/
https://www.ncbi.nlm.nih.gov/pubmed/9652769
_version_ 1782144595483688960
author Cooper, L. S.
Gillett, C. E.
Smith, P.
Fentiman, I. S.
Barnes, D. M.
author_facet Cooper, L. S.
Gillett, C. E.
Smith, P.
Fentiman, I. S.
Barnes, D. M.
author_sort Cooper, L. S.
collection PubMed
description We have investigated the use of the antibody MIB1 as a proliferative and prognostic marker in breast cancer and whether changes in proliferative activity could account for differences in prognosis of premenopausal women operated on during different phases of the menstrual cycle. MIB1 expression was strongly correlated with S-phase fraction and histological grade. There was no difference in MIB1 scores between different phases of the menstrual cycle. Both MIB1 score and timing of surgery correlated significantly with duration of survival, while the two together were even stronger predictors of overall survival. Women with slowly proliferating tumours surgically removed in the luteal phase had a very good prognosis, whereas women with rapidly proliferating tumours excised at other times of the cycle had a worse prognosis. IMAGES:
format Text
id pubmed-2150202
institution National Center for Biotechnology Information
language English
publishDate 1998
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-21502022009-09-10 Cell proliferation measured by MIB1 and timing of surgery for breast cancer. Cooper, L. S. Gillett, C. E. Smith, P. Fentiman, I. S. Barnes, D. M. Br J Cancer Research Article We have investigated the use of the antibody MIB1 as a proliferative and prognostic marker in breast cancer and whether changes in proliferative activity could account for differences in prognosis of premenopausal women operated on during different phases of the menstrual cycle. MIB1 expression was strongly correlated with S-phase fraction and histological grade. There was no difference in MIB1 scores between different phases of the menstrual cycle. Both MIB1 score and timing of surgery correlated significantly with duration of survival, while the two together were even stronger predictors of overall survival. Women with slowly proliferating tumours surgically removed in the luteal phase had a very good prognosis, whereas women with rapidly proliferating tumours excised at other times of the cycle had a worse prognosis. IMAGES: Nature Publishing Group 1998-05 /pmc/articles/PMC2150202/ /pubmed/9652769 Text en https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Research Article
Cooper, L. S.
Gillett, C. E.
Smith, P.
Fentiman, I. S.
Barnes, D. M.
Cell proliferation measured by MIB1 and timing of surgery for breast cancer.
title Cell proliferation measured by MIB1 and timing of surgery for breast cancer.
title_full Cell proliferation measured by MIB1 and timing of surgery for breast cancer.
title_fullStr Cell proliferation measured by MIB1 and timing of surgery for breast cancer.
title_full_unstemmed Cell proliferation measured by MIB1 and timing of surgery for breast cancer.
title_short Cell proliferation measured by MIB1 and timing of surgery for breast cancer.
title_sort cell proliferation measured by mib1 and timing of surgery for breast cancer.
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2150202/
https://www.ncbi.nlm.nih.gov/pubmed/9652769
work_keys_str_mv AT cooperls cellproliferationmeasuredbymib1andtimingofsurgeryforbreastcancer
AT gillettce cellproliferationmeasuredbymib1andtimingofsurgeryforbreastcancer
AT smithp cellproliferationmeasuredbymib1andtimingofsurgeryforbreastcancer
AT fentimanis cellproliferationmeasuredbymib1andtimingofsurgeryforbreastcancer
AT barnesdm cellproliferationmeasuredbymib1andtimingofsurgeryforbreastcancer

Ejemplares similares